Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/481265a | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results.
Gynecol Oncol
January 2025
University of Siena and Center for Immuno-Oncology, Department of Oncology, University Hospital, Siena, Italy. Electronic address:
Objective: We report updated results with longer follow-up in patients with MSI-H/dMMR endometrial cancer (EC) in cohort D (advanced EC of any MSI/dMMR status) and cohort K (any MSI-H/dMMR advanced solid tumor, except colorectal) of the phase 2 KEYNOTE-158 study (NCT02628067) and the first results from patients with non-MSI-H/non-dMMR advanced EC (cohort D).
Methods: Patients received pembrolizumab 200 mg Q3W for ≥35 cycles. The primary endpoint was objective response rate (ORR) per RECIST v1.
Personalising glioblastoma medicine: explant organoid applications, challenges and future perspectives.
Acta Neuropathol Commun
January 2025
Sid Faithfull Brain Cancer Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.
Glioblastoma (GBM) is a highly aggressive adult brain cancer, characterised by poor prognosis and a dismal five-year survival rate. Despite significant knowledge gains in tumour biology, meaningful advances in patient survival remain elusive. The field of neuro-oncology faces many disease obstacles, one being the paucity of faithful models to advance preclinical research and guide personalised medicine approaches.
View Article and Find Full Text PDFCombined immune checkpoint blockade (ICB) and chemoradiation (CRT) is approved in patients with locally advanced cervical cancer (LACC) but optimal sequencing of CRT and ICB is unknown. NRG-GY017 (NCT03738228) was a randomized phase I trial of atezolizumab (anti-PD-L1) neoadjuvant and concurrent with CRT (Arm A) vs. concurrent with CRT (Arm B) in patients with high-risk node-positive LACC.
View Article and Find Full Text PDFExploring the perspectives of healthcare workers and Program managers on the use of Truenat as a new tool for TB and DR-TB diagnosis in Nigeria: A qualitative study.
PLoS One
January 2025
Department of Community Medicine, College of Health Sciences, Ebonyi State University, Abakaliki, Nigeria.
Background: World Health Organization in the year 2020 recommended the use of Truenat as a replacement for smear microscopy in Tuberculosis (TB) diagnosis and detection of rifampicin resistance. This study was designed to assess enablers and barriers to effective implementation of Truenat assays for TB diagnosis in Nigeria and determine the acceptability of use of Truenat among healthcare workers and TB Program managers in Nigeria.
Methods: A descriptive exploratory study design was used.
[Carbon Peak and Carbon Neutrality Scenarios for Key Industries in Jiangsu Province Based on LEAP Model].
Huan Jing Ke Xue
January 2025
School of Energy and Mechanical Engineering, Nanjing Normal University, Nanjing 210046, China.
In this study, strategies for meeting the carbon peak and carbon neutral targets are developed through an in-depth analysis of future energy demand and carbon emission scenarios in Jiangsu Province. The LEAP model was used to forecast energy demand and carbon emissions under different scenarios from 2021 to 2060. Under the baseline scenario, the energy demand of key industries in Jiangsu Province showed a high rate of growth, with energy consumption increasing by 2.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!